Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

 Dear Sir/Madam, With reference to the Press Release on the above mentioned subject released by the Company earlier today, the Universal Dial-in Number mentioned in the Press Release may please be read as follows: Universal Dial In +91 22 6280 1278 +91 22 7115 8179 The Updated Press Release with the correct universal dial-in details is enclosed herewith for your ready reference and dissemination. The inconvenience caused is regretted.
19-08-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release on the above mentioned subject being released by the Company, which is self-explanatory. We request you to kindly take the same on record.
19-08-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2CINL73100GJ2006PLC047837 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 68.34 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: DEBASHIS DEY Designation: COMPANY SECRETARY EmailId: debashis.dey@sparcmail.com Name of the Chief Financial Officer: CHETAN RAJPARA Designation: CFO EmailId: chetan.rajpara@sparcmail.com Date: 12/08/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
12-08-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2CINL73100GJ2006PLC047837 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 68.34 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: DEBASHIS DEY Designation: COMPANY SECRETARY EmailId: debashis.dey@sparcmail.com Name of the Chief Financial Officer: CHETAN RAJPARA Designation: CFO EmailId: chetan.rajpara@sparcmail.com Date: 12/08/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
12-08-2020
Bigul

SPARC back in the black in Q1, reports profit of Rs 57 cr; stock jumps 14%

 It's revenue from operations for the quarter under review came in at Rs 185.45 crore, clocking a growth of 970.73 per cent YoY from Rs17.32 crore reported in Q1FY20
05-08-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of Board Meeting Held On 4Th August 2020

 The Board of Directors of the Company at their meeting held from 06:00 pm to 08:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 30th June 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I.
04-08-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Notice Of Board Meeting For Consideration Of Unaudited Financial Results Of The Company For The First Quarter Ended 30Th June 2020.

 SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2020 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Tuesday, 4th August 2020, inter alia, to consider and approve, the unaudited financial results of the Company for the quarter ended 30th June 2020. In view of the above and pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 6th August 2020 i.e. 48 hours after the declaration of unaudited financial results of the Company on 4th August 2020.
24-07-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that the share certificate(s) as per attached details, issued by the Company, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen.
22-07-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Shareholding for the Period Ended June 30, 2020

 Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here
17-07-2020
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement Of Investor Complaints For The Quarter Ended June 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- DEBASHIS DEYDesignation :- Company Secretary and Compliance Officer
17-07-2020
Next Page
Close

Let's Open Free Demat Account